Expression of peroxisome proliferator‐activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists

Recent studies have demonstrated that peroxisome proliferator activator‐receptors(PPAR)‐γ is expressed in various cancer tissues and its ligand induces growth arrest of these cancer cells through apoptosis. In our study, we investigated the expression of PPAR‐α, β and γ in human bladder tumor (BT) and normal bladder (NB) tissues as well as the effects of PPAR‐γ ligands. Specimens were obtained from 170 patients with BT and 20 with NB. The expressions were investigated using RT‐PCR and immunohistochemical methods. We also investigated the inhibitory effect of PPAR‐γ ligands on BT‐derived cell line. Immunoreactive PPAR‐α and ‐β were significantly apparent in both BT and NB tissues. Although no marked expression of PPAR‐γ was observed in NB tissue, significant expression was found in BT tissue. The extent and intensity of immunoreactive PPAR‐γ polypeptides in BT cells were statistically much greater than those of NB cells. Correlation between PPAR‐γ expression and tissue type or progression of bladder cancer was observed; PPAR‐γ expression was higher in G3 of bladder cancer than in G1 and was higher in advanced than in early cancer. PPAR‐γ agonists, troglitazone and 15‐deoxy‐Δ12, 14‐prostaglandin J2 inhibited the growth of the BT cells. PPAR‐γ is expressed in bladder tumor, and results suggest that PPAR‐γ ligands may mediate potent antiproliferative effects against BT cells. Thus, PPAR‐γ has the ability to become a new target in treatment of bladder tumor. © 2003 Wiley‐Liss, Inc.

[1]  Y. Kawahito,et al.  Expression of Peroxisome Proliferator-Activated Receptor γ in Renal Cell Carcinoma and Growth Inhibition by Its Agonists , 2001 .

[2]  T. Okumura,et al.  Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. , 2000, Cancer research.

[3]  G. Martiny-Baron,et al.  Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. , 2000, Cancer research.

[4]  M. Kondo,et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. , 2000, Biochemical and biophysical research communications.

[5]  T. Chang,et al.  Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. , 2000, Cancer research.

[6]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[7]  T. Okumura,et al.  Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .

[8]  T. Hla,et al.  Endothelial Cell Apoptosis Induced by the Peroxisome Proliferator-activated Receptor (PPAR) Ligand 15-Deoxy-Δ12,14-prostaglandin J2 * , 1999, The Journal of Biological Chemistry.

[9]  Rajnish A. Gupta,et al.  Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells , 1998 .

[10]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[11]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[12]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[14]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[15]  J. Auwerx,et al.  Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.

[16]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[17]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[18]  C. Winrow,et al.  Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes , 1996, Molecular and Cellular Endocrinology.

[19]  J. Auwerx,et al.  Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm (*) , 1996, The Journal of Biological Chemistry.

[20]  S. Reddy,et al.  Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. , 1993, The Journal of biological chemistry.

[21]  E. Remmers,et al.  Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. , 1993, The Journal of clinical investigation.

[22]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[23]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[24]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[25]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[26]  M. Sporn,et al.  Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. , 1989, Journal of immunology.

[27]  Fabienne,et al.  Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution of PPAR-a, $3, and -y in the Adult Rat* , 2001 .

[28]  S. Fitzgerald,et al.  Evaluating research studies using the analysis of variance (ANOVA): issues and interpretations. , 2000, Journal of hand therapy : official journal of the American Society of Hand Therapists.

[29]  T. Okumura,et al.  Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. , 1999, FEBS letters.

[30]  R. DuBois,et al.  Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. , 1998, Gastroenterology.

[31]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.